BioMarin Pharmaceutical | BMRN - Operating Profit

Stock Price
57.62
Daily Change
0.01 0.02%
Monthly
-2.12%
Yearly
-10.23%
Q1 Forecast
54.80

BioMarin Pharmaceutical reported $-31.69M in Operating Profit for its fiscal quarter ending in September of 2025.





Operating Profit Change Date
Acadia Pharmaceuticals USD 35.76M 3.38M Sep/2025
Agios Pharmaceuticals USD -116.87M 10.19M Sep/2025
Alnylam Pharmaceuticals USD -29.96M 13.76M Sep/2025
Amgen USD 3.96B 464M Dec/2025
Bayer EUR -543M 556M Sep/2025
Biogen USD 659.6M 192.2M Sep/2025
BioMarin Pharmaceutical USD -31.69M 308.58M Sep/2025
Gilead Sciences USD 3.51B 810M Sep/2025
Incyte USD 431.31M 120.49M Sep/2025
Insmed USD -261.35M 7.48M Sep/2025
Ionis Pharmaceuticals USD -160.18M 300.02M Sep/2025
Moderna USD -260M 647M Sep/2025
Neurocrine Biosciences USD 239.3M 93.7M Sep/2025
PTC Therapeutics USD 3.49M 38.35M Sep/2025
Regeneron Pharmaceuticals USD 898.6M 211.3M Dec/2025
Roche Holding CHF 9.56B 3.8B Dec/2025
Sanofi EUR 1.5B 2.29B Dec/2025
Sarepta Therapeutics USD -62.88M 178.46M Sep/2025
Ultragenyx Pharmaceutical USD -170.89M 22.68M Sep/2025
United Therapeutics USD 389.3M 112.4M Sep/2025
Vertex Pharmaceuticals USD 1.24B 84.6M Sep/2025